Jubilant Ingrevia Ltd announced the acquisition of Remidex Pharma Private Limited for ₹165 million. The deal involves a 100% stake purchase and will be completed within 30 days. Remidex specializes in micronutrient premixes and nutraceuticals, enabling Jubilant to expand its human nutrition portfolio and strengthen its leadership in specialty chemicals.
Introduction To The Announcement
On March 13, 2026, Jubilant Ingrevia Ltd disclosed via exchange filings that it has entered into a definitive share purchase agreement with Remidex Pharma. The acquisition is valued at ₹16.5 crore and will make Remidex a wholly owned subsidiary of Jubilant Ingrevia.
Acquisition Details
-
Buyer: Jubilant Ingrevia Ltd
-
Target: Remidex Pharma Private Limited, Bangalore-based firm established in 1981
-
Stake: 100% acquisition
-
Deal value: ₹16.5 crore (₹165 million)
-
Completion timeline: Within 30 days
-
Remidex FY24-25 turnover: ₹24.27 crore
Strategic Importance
The acquisition strengthens Jubilant’s position in the human nutrition value chain, particularly in premixes for micronutrients and nutraceuticals. It complements Jubilant’s leadership in vitamins B3 and B4, expanding its product offerings and market reach.
Broader Implications
This deal reflects Jubilant’s strategy of diversifying into high-growth sectors like nutrition and life sciences. It also highlights consolidation trends in India’s pharmaceutical and nutraceutical industries, where established players are acquiring niche firms to expand capabilities.
Key Highlights
• Jubilant Ingrevia acquires Remidex Pharma for ₹16.5 crore
• 100% stake purchase confirmed via definitive agreement
• Remidex specializes in micronutrient premixes and nutraceuticals
• Acquisition to be completed within 30 days
• Strengthens Jubilant’s human nutrition and specialty chemicals portfolio
Sources: InvestyWise, ScanX News, Business Upturn